Adam Frome, MD
Nephrology · The Woodlands, TXNPI 1215124417
Payments from drug & device makers
Across 573 payments — averaging $5383.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$834K
- CSL Behring$745K
- Astrazeneca UK Limited$438K
- Vertex$415K
- AstraZeneca$324K
- Boehringer Ingelheim International GmbH$88K
- plus $240K from 30 others
Across 7 payments — averaging $9822.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$69K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 15 | $834,248 |
| CSL Behring | 94 | $745,431 |
| Astrazeneca UK Limited | 6 | $438,083 |
| Vertex | 3 | $415,167 |
| AstraZeneca | 60 | $324,448 |
| Boehringer Ingelheim International GmbH | 20 | $87,639 |
| Bayer | 56 | $85,631 |
| Akebia Therapeutics Inc | 115 | $82,281 |
| Boehringer Ingelheim | 12 | $56,016 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 6 | $8,909 |
| Boehringer Ingelheim Limited | 4 | $2,788 |
| Otsuka America Pharmaceutical, Inc. | 28 | $587 |
| Travere Therapeutics, Inc. | 16 | $528 |
| Amgen(2 entities) | 19 | $396 |
| Novartis | 18 | $392 |
| Calliditas Therapeutics US Inc. | 14 | $330 |
| Vifor Pharma, Inc. | 15 | $289 |
| Mallinckrodt Hospital Products Inc. | 8 | $288 |
| Novo Nordisk | 10 | $219 |
| GSK | 9 | $203 |
| Recor Medical Inc | 7 | $151 |
| Lilly USA, LLC | 7 | $136 |
| Scpharmaceuticals Inc. | 5 | $110 |
| ANI Pharmaceuticals, Inc. | 4 | $101 |
| Aurinia Pharma U.S., Inc. | 5 | $93 |
| Kyowa Kirin, Inc. | 3 | $60 |
| Ardelyx, Inc. | 2 | $52 |
| Alnylam Pharmaceuticals Inc. | 2 | $48 |
| Medtronic | 1 | $43 |
| Renalytix AI, Inc. | 2 | $39 |
| Sanofi | 2 | $39 |
| Fresenius USA Marketing, Inc. | 1 | $36 |
| Apellis Pharmaceuticals, Inc. | 1 | $29 |
| Ascendis Pharma Endocrinology Inc | 1 | $25 |
| AbbVie | 1 | $17 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
How this compares
$3,084,867 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in The Woodlands
- Harini BejjankiThe Woodlands$1.7M
- Pablo PergolaSan Antonio$14.2M
- German HernandezEl Paso$9.7M
- Sreedhar MandayamHouston$7M
- Tahira AlvesSan Antonio$6.1M
- Carl DukesSan Antonio$5.9M
- Chinonye Ogbonnaya-OdorSan Antonio$4.6M
- Marializa BernardoHouston$4.2M
- Judith BettsAustin$3.7M
- Wesley CalhounSan Antonio$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.